{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:51:53Z","timestamp":1779911513847,"version":"3.53.1"},"reference-count":47,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation &amp;lt;95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital\/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29\u20130.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc20-1521","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T19:10:18Z","timestamp":1601406618000},"page":"2999-3006","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":221,"title":["Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study"],"prefix":"10.2337","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct04365517","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04382794","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"Sebastiano Bruno","family":"Solerte","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Geriatric and Diabetology Unit, University of Pavia, Italy"},{"name":"School of Geriatrics, University of Pavia Azienda di Servizi alla Persona-Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Addio","sequence":"additional","affiliation":[{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Universit\u00e0 di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Malattie Endocrine 1-Diabetologia, Ospedale Papa Giovanni XXIII Azienda Socio Sanitaria Territoriale-PG XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Lovati","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, University of Pavia and IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Pastore","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Dell\u2019Acqua","sequence":"additional","affiliation":[{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Universit\u00e0 di Milano, Milan, Italy"},{"name":"Division of Endocrinology, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Ippolito","sequence":"additional","affiliation":[{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Universit\u00e0 di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Scaranna","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Malattie Endocrine 1-Diabetologia, Ospedale Papa Giovanni XXIII Azienda Socio Sanitaria Territoriale-PG XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Bellante","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Malattie Endocrine 1-Diabetologia, Ospedale Papa Giovanni XXIII Azienda Socio Sanitaria Territoriale-PG XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Galliani","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Malattie Endocrine 1-Diabetologia, Ospedale Papa Giovanni XXIII Azienda Socio Sanitaria Territoriale-PG XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Roberto","family":"Dodesini","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Malattie Endocrine 1-Diabetologia, Ospedale Papa Giovanni XXIII Azienda Socio Sanitaria Territoriale-PG XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lepore","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa Malattie Endocrine 1-Diabetologia, Ospedale Papa Giovanni XXIII Azienda Socio Sanitaria Territoriale-PG XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Geni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Geriatric and Diabetology Unit, University of Pavia, Italy"},{"name":"School of Geriatrics, University of Pavia Azienda di Servizi alla Persona-Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Maria","family":"Fiorina","sequence":"additional","affiliation":[{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Universit\u00e0 di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Catena","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Luigi Sacco Hospital, Universit\u00e0 di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Corsico","sequence":"additional","affiliation":[{"name":"Pneumology Unit, Fondazione IRCCS Policlinico San Matteo and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care Unit, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Luigi Sacco Hospital, Universit\u00e0 di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mirani","sequence":"additional","affiliation":[{"name":"Endocrinology and Diabetology Unit, Humanitas Research Hospital, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"De Riva","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa di Malattie Endocrine ULSS3-Ospedale dell\u2019Angelo Mestre, Mestre, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Endrio","family":"Oleandri","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Azienda Sanitaria Locale Citt\u00e0 di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-5422","authenticated-orcid":false,"given":"Reza","family":"Abdi","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Bonventre","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences \u201cLuigi Sacco,\u201d Univerist\u00e0 di Milano, Milan, Italy"},{"name":"III Division of Infectious Diseases, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-5222","authenticated-orcid":false,"given":"Franco","family":"Folli","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Health Science, Universit\u00e0 di Milano, Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, University of Pavia and IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianvincenzo","family":"Zuccotti","sequence":"additional","affiliation":[{"name":"Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche, Universit\u00e0 di Milano, Milan, Italy"},{"name":"Department of Pediatrics, \u201cV. Buzzi\u201d Children's Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Galli","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences \u201cLuigi Sacco,\u201d Univerist\u00e0 di Milano, Milan, Italy"},{"name":"III Division of Infectious Diseases, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1093-7724","authenticated-orcid":false,"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[{"name":"International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Universit\u00e0 di Milano, Milan, Italy"},{"name":"Division of Endocrinology, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy"},{"name":"Division of Nephrology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"2022031220344410200_B1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031220344410200_B2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2022031220344410200_B3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2337\/dbi19-0023","article-title":"Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19","volume":"69","author":"Mauvais-Jarvis","year":"2020","journal-title":"Diabetes"},{"key":"2022031220344410200_B4","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: what next","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"key":"2022031220344410200_B5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2022031220344410200_B6","doi-asserted-by":"crossref","first-page":"101400","DOI":"10.1016\/j.isci.2020.101400","article-title":"The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike","volume":"23","author":"Li","year":"2020","journal-title":"iScience"},{"key":"2022031220344410200_B7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/22221751.2020.1739565","article-title":"Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26","volume":"9","author":"Vankadari","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2022031220344410200_B8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.03.044","article-title":"Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses","volume":"526","author":"Qi","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"2022031220344410200_B9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"2022031220344410200_B10","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031220344410200_B11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2022031220344410200_B12","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"2022031220344410200_B13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J Med Chem"},{"key":"2022031220344410200_B14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/ciy1051","article-title":"A randomized, double-blinded, placebo-controlled trial of sitagliptin for reducing inflammation and immune activation in treated and suppressed human immunodeficiency virus infection","volume":"69","author":"Dub\u00e9","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022031220344410200_B15","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1210\/jc.2012-1544","article-title":"Sitagliptin exerts an antinflammatory action","volume":"97","author":"Makdissi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031220344410200_B16","doi-asserted-by":"crossref","first-page":"104405","DOI":"10.1016\/j.phrs.2019.104405","article-title":"Sitagliptin favorably modulates immune-relevant pathways in human beta cells","volume":"148","author":"Malvandi","year":"2019","journal-title":"Pharmacol Res"},{"key":"2022031220344410200_B17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1499-3872(14)60308-8","article-title":"Dipeptidyl peptidase-4 inhibitor sitagliptin significantly reduced hepatitis C virus replication in a diabetic patient with chronic hepatitis C virus infection","volume":"13","author":"Yanai","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2022031220344410200_B18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s12020-016-1073-8","article-title":"DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-\u03baB activation","volume":"55","author":"Hu","year":"2017","journal-title":"Endocrine"},{"key":"2022031220344410200_B19","doi-asserted-by":"crossref","first-page":"bnaa011","DOI":"10.1210\/endrev\/bnaa011","article-title":"Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications","volume":"41","author":"Drucker","year":"2020","journal-title":"Endocr Rev"},{"key":"2022031220344410200_B20","doi-asserted-by":"crossref","first-page":"108125","DOI":"10.1016\/j.diabres.2020.108125","article-title":"COVID-19 and diabetes: can DPP4 inhibition play a role","volume":"162","author":"Iacobellis","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031220344410200_B21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00592-020-01539-z","article-title":"Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19","volume":"57","author":"Solerte","year":"2020","journal-title":"Acta Diabetol"},{"key":"2022031220344410200_B22","doi-asserted-by":"crossref","first-page":"e3330","DOI":"10.1002\/dmrr.3330","article-title":"DPP4 inhibition: preventing SARS-CoV-2 infection and\/or progression of COVID-19","author":"Strollo","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031220344410200_B23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40618-020-01236-2","article-title":"Prevalence and impact of diabetes among people infected with SARS-CoV-2","volume":"43","author":"Fadini","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"2022031220344410200_B24","doi-asserted-by":"crossref","first-page":"e001343","DOI":"10.1136\/bmjdrc-2020-001343","article-title":"Clinical characteristics and outcomes of patients with severe covid-19 with diabetes","volume":"8","author":"Yan","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2022031220344410200_B25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.metabol.2019.02.004","article-title":"Beyond glycemic control: new guidance on cardio-renal protection","volume":"99","author":"Anastasilakis","year":"2019","journal-title":"Metabolism"},{"key":"2022031220344410200_B26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tem.2016.04.005","article-title":"Type 1 diabetes and dysfunctional intestinal homeostasis","volume":"27","author":"D\u2019Addio","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"2022031220344410200_B27","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022031220344410200_B28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2013050518","article-title":"Role of podocyte B7-1 in diabetic nephropathy","volume":"25","author":"Fiorina","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022031220344410200_B29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4239\/wjd.v6.i7.889","article-title":"Explaining the increased mortality in type 1 diabetes","volume":"6","author":"Mameli","year":"2015","journal-title":"World J Diabetes"},{"key":"2022031220344410200_B30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jama.2015.9536","article-title":"Diabetes: advances in diagnosis and treatment","volume":"314","author":"Nathan","year":"2015","journal-title":"JAMA"},{"key":"2022031220344410200_B31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"2022031220344410200_B32","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.2337\/dc20-S001","article-title":"1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes\u20142020","volume":"43","author":"Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2022031220344410200_B33","unstructured":"Societ\u00e0 Italiana Diabetologia . CS AMD SID 7 aprile 20 (in Italian), 2020. Accessed 4 July 2020. Available from http:\/\/www.siditalia.it\/pdf\/coronavirus\/CS_AMD_SID_7aprile20.pdf"},{"key":"2022031220344410200_B34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12933-020-01089-2","article-title":"Issues for the management of people with diabetes and COVID-19 in ICU","volume":"19","author":"Ceriello","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2022031220344410200_B35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41586-020-2488-1","article-title":"Suppression of a SARS-CoV-2 outbreak in the Italian municipality of vo\u2019","volume":"584","author":"Lavezzo","year":"2020","journal-title":"Nature"},{"key":"2022031220344410200_B36","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2022031220344410200_B37","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1056\/NEJMc2011599","article-title":"Adaptations and lessons in the Province of Bergamo","volume":"382","author":"Fagiuoli","year":"2020","journal-title":"N Engl J Med"},{"key":"2022031220344410200_B38","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2468-2667(20)30099-2","article-title":"COVID-19 deaths in Lombardy, Italy: data in context","volume":"5","author":"Odone","year":"2020","journal-title":"Lancet Public Health"},{"key":"2022031220344410200_B39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2165\/11591400-000000000-00000","article-title":"Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences","volume":"71","author":"Baetta","year":"2011","journal-title":"Drugs"},{"key":"2022031220344410200_B40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022031220344410200_B41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/dom.12610","article-title":"Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas","volume":"18","author":"Deacon","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022031220344410200_B42","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"2022031220344410200_B43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejps.2016.12.040","article-title":"Sitagliptin inhibit human lymphocytes proliferation and Th1\/Th17 differentiation in vitro","volume":"100","author":"Pinheiro","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"2022031220344410200_B44","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab"},{"key":"2022031220344410200_B45","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2337\/dc20-0660","article-title":"Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"2022031220344410200_B46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00592-018-1257-1","article-title":"The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis","volume":"56","author":"Carnovale","year":"2019","journal-title":"Acta Diabetol"},{"key":"2022031220344410200_B47","first-page":"320","article-title":"Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition","volume-title":"Cell Metab","author":"Varin","year":"2019"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/12\/2999\/531115\/dc201521.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/43\/12\/2999\/531115\/dc201521.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T16:53:52Z","timestamp":1696784032000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/43\/12\/2999\/30924\/Sitagliptin-Treatment-at-the-Time-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,29]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-1521","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}